Evidence map›Paper›PMID 40569175›Full record

ArticleJournal of medicinal chemistry2025

Novel Tetraolefinic Chain Phenyl Substituted Endocannabinoid Probes.

Markos-Orestis Georgiadis, Lipin Ji, Fei Tong, Vuong Q Dang, Luana Assis Ferreira, Alexandra Faragher, Ngan Tran, Anastasiia V Sadybekov, Suthakar Ganapathy, Nikolai Zvonok and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Exceptionally Potent Chiral Anandamide Analogs.Journal of medicinal chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Markos-Orestis GeorgiadisCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.
Lipin JiCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.
Fei TongCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.ORCID 0000-0003-2880-8135
Vuong Q DangDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida 33458, United States.
Luana Assis FerreiraPsychological and Brain Sciences, Indiana University, Bloomington, Indianna, 47405, United States.
Alexandra FaragherDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida 33458, United States.
Ngan TranCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.
Anastasiia V SadybekovDepartment of Quantitative and Computational Biology, and Department of Chemistry, Bridge Institute, Center for New Technologies in Drug Discovery and Development, University of Southern California, Los Angeles, California 90089, United States.ORCID 0000-0003-3925-983X
Suthakar GanapathyCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.
Nikolai ZvonokCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.
Vsevolod KatritchDepartment of Quantitative and Computational Biology, and Department of Chemistry, Bridge Institute, Center for New Technologies in Drug Discovery and Development, University of Southern California, Los Angeles, California 90089, United States.ORCID 0000-0003-3883-4505
Andrea G HohmannPsychological and Brain Sciences, Indiana University, Bloomington, Indianna, 47405, United States.
Laura M BohnDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, Florida 33458, United States.ORCID 0000-0002-6474-8179
Alexandros MakriyannisCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.ORCID 0000-0003-3272-3687
Spyros P NikasCenter for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States.ORCID 0000-0001-5052-5292

Funding

Project 3 - In vivo pharmacology of cannabinoid receptor probesP01DA009158 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI Alexandros Makriyannis · 1994 to 2026
$26.0M
NIDA NIH HHS P01 DA009158
6 · The paper itself

Abstract

We report the development of novel endocannabinoid analogs carrying phenyl rings in judiciously chosen positions within the tetraolefinic chain pharmacophore of the endogenous

Indexed as

AnalgesicsEndocannabinoidsAnimalsArachidonic AcidsGlyceridesHumansMaleMiceMolecular Docking SimulationRatsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Structure-Activity RelationshipAnalgesicsArachidonic AcidsEndocannabinoidsGlyceridesglyceryl 2-arachidonateReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2

Identifiers

PMID40569175
PMCPMC12921924

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.